Dose-escalation, Repeated and Single Oral Dosing Study

Acute Coronary Syndrome Clinical Trial

Official title:

Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Temanogrel Co-administered With Aspirin and Clopidogrel

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02419820
• Other study ID #: ID-TMG-102
• Status: Terminated
• Phase: Phase 1
• Start date: March 2015
• Est. completion date: April 2016

Study information

• Verified date: February 2019
• Source: IlDong Pharmaceutical Co Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of APD791 (Temanogrel) Co-administered with Aspirin and Clopidogrel.

Description:

1. To investigate pharmacokinetic and pharmacodynamic characteristics of Temanogrel when orally co-administered with Aspirin and/or Clopidogrel in healthy subject. a person determined to be suitable for the purpose of this clinical trial by investigator with consideration for the age and the health status of a volunteer is selected

2. Assess the safety of Temanogrel when orally co-administered with Aspirin and/or Clopidogrel in healthy subjects.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 104
• Est. completion date: April 2016
• Est. primary completion date: April 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 45 Years

Eligibility

Inclusion Criteria:

1. a healthy adult between 20 and 45 years old at the time of visit for screening

2. a person who is able to give written consent

3. a person between 50 and 85 kg at the time of visit for screening

4. a woman who is negative on a serum hCG test at the time of visit and the day before a trial, and who is not nursing, a woman who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, or who had a contraceptive operation no later than 120 days before visit for screening, or who is menopausal, a man who had a contraceptive operation no later than 120 days before visit for screening, or who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, and also agree not to donate sperm

5. a person more than hemoglobin 12 g/dL at the time of screening (a woman more than hemoglobin 11 g/dL)

6. a person whose vital signs were in the normal range at the time of visit for screening, or who is medically determined not to be clinically significant by an investigator

Exclusion Criteria:

1. a person with the medical history of gastric ulcer, duodenal ulcer or esophageal ulcer within 90 days from the time of visit for screening

2. a person with the medical history of gastrointestinal diseases(e.g. Crohn's disease, ulcerative colitis, etc.) or surgery(excluding uncomplicated appendectomy or herniotomy) affecting the absorption of a clinical trial drug

3. a person with the medical history of blood coagulation disorder or hemorrhagic diseases, or with clinically significant abnormal findings decided by a investigator on blood coagulation test at the time of screening

4. a woman with the medical history of dysfunctional uterine bleeding within a year from the time of visit for screening

5. a person with the medical history of epilepsy or convulsion

6. a person with the medical history of internal organ transplant

7. a person expected to be hard to complete a clinical trial because of surgery or medical procedures planned within a clinical trial period

8. a person with the medical history of clinically significant new diseases within 30 days from the time of visit for screening according to investigator's decision

9. a person with hypersensitivity reaction to a drug or gelatin, or the medical history of clinically significant hypersensitivity reaction

10. a person with the history of drug abuse, or with a positive reaction to a drug possible to be abused on urine drug screening

11. a person with the medical history of alcohol abuse within two years from the time of visit for screening

12. a person who is a smoker, or with a positive reaction on a urine nicotine test conducted at the time of visit for screening

13. a person who donated whole blood within 60 days or constituents of blood within 30 days, or received a blood transfusion within 30 days from the time of visit for screening

14. a person taking other clinical trial drugs within 90 days from the time of visit for screening

15. a person taking a prescription drug within 30 days, or a contraindicated drug or oriental medicine within 14 days from the time of visit for screening

16. a person with a positive reaction to a serum test(hepatitis B test, hepatitis C test, HIV test, syphilis test)

17. a person with hepatic enzymes(AST, ALT) more than 2.5 times of the reference upper limit(UNL) or total bilirubin more than 1.5 times of the reference upper limit(UNL) or creatinine more than 1.25 times of the reference upper limit(UNL)

18. a person expected to be hard to complete a clinical trial due to physical or mental status according to investigator's medical decision at the time of visit for screening

Related Conditions & MeSH terms

• Acute Coronary Syndrome

Intervention

Drug:
• APD791
Temanogrel
• Clopidogrel
Clopidogrel
• Aspirin
Aspirin
• Placebo for APD791
Placebo for APD791

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
IlDong Pharmaceutical Co Ltd	Asan Medical Center

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics-Cmax		Day1, Day2, Day3, Day4, Day 7
Primary	Pharmacokinetics-Tmax		Day1, Day2, Day3, Day4, Day 7
Primary	Pharmacodynamics-% inhibition of serotonin-stimulated platelet aggregation		Day1, Day2, Day4, Day7, Day 8
Primary	Pharmacodynamics-change of serotonin-stimulated platelet aggregation		Day1, Day4, Day7
Primary	Pharmacodynamics-% inhibition of TRAP-induced platelet aggregation		Day1, Day4, Day7 of every dose for mutiple dose group and first day for single dose group.
Secondary	adverse event monitoring		up to post-study visit(8day±2)
Secondary	physical examination		up to post-study visit(8day±2)
Secondary	vital signs		up to post-study visit(8day±2)
Secondary	ECG		up to post-study visit(8day±2)
Secondary	laboratory test		up to post-study visit(8day±2)